文献速递胸部肿瘤

达克替尼对比吉非替尼一线治疗EGFR突变阳性非小细胞肺癌(ARCHER 1050)

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-09-25

ARCHER 1050是一项国际多中心随机开放标签3期研究,纳入452例新诊断晚期EGFR突变阳性非小细胞肺癌患者,1:1随机接受达克替尼45 mg/日或吉非替尼250 mg/日。盲法独立评审的中位无进展生存期为达克替尼组14.7个月 vs 吉非替尼组9.2个月(HR 0.59,95%CI 0.47-0.74;p<0.0001)。作者认为达克替尼显著改善无进展生存期,应被视为该人群新的治疗选择。

要点

  • 盲法独立评审中位无进展生存期达克替尼组14.7个月 vs 吉非替尼组9.2个月(HR 0.59)。
  • 3-4级皮炎痤疮样皮疹达克替尼组31/227例(14%) vs 吉非替尼组0/224例。
  • 治疗相关严重不良事件达克替尼组21例(9%) vs 吉非替尼组10例(4%)。

核心结论

  • 达克替尼在EGFR突变阳性非小细胞肺癌一线治疗中较吉非替尼显著改善无进展生存期,作者认为应将其视为该人群新的治疗选择。

研究设计与样本

  • 国际、多中心、随机、开放标签3期研究(ARCHER 1050),在7个国家或特别行政区的71个学术医疗中心和大学医院开展。
  • 纳入新诊断晚期非小细胞肺癌且伴一种EGFR突变(19外显子缺失或Leu858Arg)的成人(年龄≥18岁,日本和韩国≥20岁)。
  • 按1:1随机分配接受口服达克替尼45 mg/日(28天为一周期)或口服吉非替尼250 mg/日(28天为一周期),直至疾病进展或符合其他停药标准。
  • 随机化按种族和EGFR突变类型分层,由中央交互式网络应答系统分配计算机生成的随机编码。
  • 主要终点为意向治疗人群中经盲法独立评审的无进展生存期;安全性在所有至少接受一剂研究治疗的患者中评估。

主要发现

  • 2013年5月9日至2015年3月20日,452例符合条件的患者被随机分配接受达克替尼(n=227)或吉非替尼(n=225)。
  • 无进展生存期的中位随访时间为22.1个月(95%CI 20.3-23.9)。
  • 盲法独立评审的中位无进展生存期达克替尼组为14.7个月(95%CI 11.1-16.6),吉非替尼组为9.2个月(95%CI 9.1-11.0)(HR 0.59,95%CI 0.47-0.74;p<0.0001)。
  • 最常见的3-4级不良事件为皮炎痤疮样皮疹(达克替尼组31/227例[14%] vs 吉非替尼组0/224例)、腹泻(达克替尼组19例[8%] vs 吉非替尼组2例[1%])和丙氨酸氨基转移酶升高(达克替尼组2例[1%] vs 吉非替尼组19例[8%])。
  • 治疗相关严重不良事件达克替尼组21例(9%) vs 吉非替尼组10例(4%);治疗相关死亡达克替尼组2例(一例与未治疗的腹泻相关,一例与未治疗的胆石症/肝病相关),吉非替尼组1例(与乙状结肠憩室炎/破裂并发肺炎相关)。

关键数值与推荐

  • 主要终点为盲法独立评审的无进展生存期,在意向治疗人群中评估。
  • 中位无进展生存期达克替尼组14.7个月(95%CI 11.1-16.6) vs 吉非替尼组9.2个月(95%CI 9.1-11.0),HR 0.59(95%CI 0.47-0.74),p<0.0001。
  • 达克替尼给药方案为口服45 mg/日,28天为一周期;吉非替尼为口服250 mg/日,28天为一周期。

临床怎么用

  • 作者认为,达克替尼在EGFR突变阳性非小细胞肺癌一线治疗中较吉非替尼显著改善无进展生存期,应被视为该人群新的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). METHODS: In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and university hospitals in seven countries or special administrative regions. We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met. Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system. The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, number NCT01774721, and is ongoing but no longer recruiting patients. FINDINGS: Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225). Median duration of follow-up for progression-free survival was 22·1 months (95% CI 20·3-23·9). Median progression-free survival according to masked independent review was 14·7 months (95% CI 11·1-16·6) in the dacomitinib group and 9·2 months (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001). The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhoea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]). Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib. Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhoea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia). INTERPRETATION: Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC and should be considered as a new treatment option for this population. FUNDING: SFJ Pharmaceuticals Group and Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017. PMID: 28958502. doi:10.1016/S1470-2045(17)30608-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。